Cover Image
市場調查報告書

橫紋肌肉瘤:開發平台分析

Rhabdomyosarcoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245966
出版日期 內容資訊 英文 147 Pages
訂單完成後即時交付
價格
Back to Top
橫紋肌肉瘤:開發平台分析 Rhabdomyosarcoma - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 147 Pages
簡介

橫紋肌肉瘤(RMS)是從正常的骨骼肌肉細胞所衍生的惡性腫瘤(癌症)。 為什麼正常的骨骼肌肉細胞會罹患癌症,目前幾乎還找不到解釋。骨骼肌肉細胞幾乎存在於人體的所有部位,所以橫紋肌肉瘤在人體的任何部位都有發病的可能。

本報告提供全球各國治療橫紋肌肉瘤所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查結果。

簡介

  • 分析範圍

橫紋肌肉瘤概要

治療藥的開發

  • 橫紋肌肉瘤開發中產品:概要
  • 橫紋肌肉瘤開發中產品:比較分析

各企業開發中的橫紋肌肉瘤治療藥

大學/研究機關研究中的橫紋肌肉瘤治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

橫紋肌肉瘤治療藥:開發中的產品一覽(各企業)

橫紋肌肉瘤治療藥:研究中的產品一覽(各大學/研究機關)

橫紋肌肉瘤開發治療藥的企業

  • Bellicum Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • EpiZyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merrimack Pharmaceuticals, Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Noxxon Pharma AG
  • 鹽野義製藥

橫紋肌肉瘤:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • afatinib dimaleate
  • bevacizumab
  • Cellular Immunotherapy for GD2 Expressing Solid Tumors
  • Cellular Immunotherapy for Oncology
  • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology
  • celyvir
  • everolimus
  • irinotecan hydrochloride
  • NOXS-93
  • ontuxizumab
  • paclitaxel albumin bound
  • pazopanib hydrochloride
  • S-588410
  • tazemetostat

橫紋肌肉瘤治療藥:最新的藥物簡介

橫紋肌肉瘤治療藥:暫停開發的產品

橫紋肌肉瘤治療藥:開發中止的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8513IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2016, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 5, 2 and 1 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 3 and 1 molecules, respectively for Rhabdomyosarcoma.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rhabdomyosarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Rhabdomyosarcoma - Overview
    • Pipeline Products for Rhabdomyosarcoma - Comparative Analysis
  • Rhabdomyosarcoma - Therapeutics under Development by Companies
  • Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes
  • Rhabdomyosarcoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Rhabdomyosarcoma - Products under Development by Companies
  • Rhabdomyosarcoma - Products under Investigation by Universities/Institutes
  • Rhabdomyosarcoma - Companies Involved in Therapeutics Development
    • Bellicum Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • Celgene Corporation
    • EpiZyme, Inc.
    • Exelixis, Inc.
    • Immunomedics, Inc.
    • Iproteos S.L.
    • Merrimack Pharmaceuticals, Inc.
    • Morphotek, Inc.
    • Novartis AG
    • Noxxon Pharma AG
    • Pfizer Inc.
    • Shionogi & Co., Ltd.
  • Rhabdomyosarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • axitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • celyvir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crizotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Hex-hR1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAL-3101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOXS-93 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ontuxizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel albumin bound - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazopanib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-588410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Rhabdomyosarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tazemetostat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rhabdomyosarcoma - Dormant Projects
  • Rhabdomyosarcoma - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rhabdomyosarcoma, H2 2016
  • Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Rhabdomyosarcoma - Pipeline by Celgene Corporation, H2 2016
  • Rhabdomyosarcoma - Pipeline by EpiZyme, Inc., H2 2016
  • Rhabdomyosarcoma - Pipeline by Exelixis, Inc., H2 2016
  • Rhabdomyosarcoma - Pipeline by Immunomedics, Inc., H2 2016
  • Rhabdomyosarcoma - Pipeline by Iproteos S.L., H2 2016
  • Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Rhabdomyosarcoma - Pipeline by Morphotek, Inc., H2 2016
  • Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2016
  • Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H2 2016
  • Rhabdomyosarcoma - Pipeline by Pfizer Inc., H2 2016
  • Rhabdomyosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Rhabdomyosarcoma - Dormant Projects, H2 2016
  • Rhabdomyosarcoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Rhabdomyosarcoma, H2 2016
  • Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top